What Does the Ozempic Label Say About Gastroparesis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Specific Risk Assessment

If you're experiencing persistent nausea, vomiting, or abdominal pain after starting Ozempic, you may be concerned about gastroparesis. Understanding the symptoms and their timing is crucial for proper documentation and care. This page reviews the prescribing information and clinical context for this potential side effect, building on decades of research into medication safety and gastrointestinal health.

The Emergence of Ozempic-Related Gastroparesis Concerns

Building on the legacy of general health information, the medical community now faces a more specific challenge: understanding and addressing the potential link between Ozempic (semaglutide) and gastroparesis. Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes and, in some formulations, for weight management. Among the adverse effects associated with its use, gastrointestinal complications have been prominently reported. Gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, has emerged as a significant concern in patients using Ozempic. This section examines the clinical presentation and diagnosis of gastroparesis, the pharmacology of Ozempic and its reported adverse effects, mechanistic pathways linking the drug to gastroparesis, adequacy of warnings, settlement-related considerations for affected patients, and the timeline between exposure and documented harm.

Clinical Presentation and Diagnosis of Gastroparesis

Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which a radiolabeled meal leaves the stomach. The condition can lead to malnutrition, dehydration, and significant impairment in quality of life. In the context of Ozempic use, these symptoms may overlap with common gastrointestinal adverse reactions reported in clinical trials. According to the FDA-approved labeling, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 15.3% for placebo, 32.7% for Ozempic 0.5 mg, and 36.4% for Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In trials with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus the 1 mg dose (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Pharmacology and Mechanistic Link to Gastroparesis

The pharmacology of Ozempic involves activation of GLP-1 receptors, which slow gastric emptying and reduce postprandial glucose excursions. This mechanism is central to its therapeutic effect but also underlies the risk of gastroparesis. Delayed gastric emptying can become pathological, leading to symptoms consistent with gastroparesis. The labeling also lists other gastrointestinal adverse reactions with a frequency of less than 5%, including dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed as a separate adverse reaction in these tables, the constellation of symptoms and the known pharmacodynamic effect on gastric motility support a mechanistic link. Mechanistically, GLP-1 receptor agonists like semaglutide inhibit gastric motility through vagal and enteric nervous system pathways. This can lead to prolonged gastric retention, which, in susceptible individuals, may progress to gastroparesis. The risk may be dose-dependent, as suggested by the higher incidence of gastrointestinal adverse reactions at higher doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Adequacy of Warnings and Settlement Considerations

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk anchor. The labeling does not explicitly mention gastroparesis as a potential adverse reaction, despite the known effect of GLP-1 agonists on gastric emptying. This omission may affect patients' ability to recognize early symptoms and seek timely medical intervention. For affected patients, settlement-related considerations may include the need to demonstrate a causal link between Ozempic use and the development of gastroparesis, as well as the severity and duration of symptoms. The timeline between exposure and documented harm is also relevant; gastrointestinal adverse reactions often occur during dose escalation, but gastroparesis may develop after prolonged use or in individuals with underlying risk factors. Patients who experience persistent symptoms despite dose adjustment or discontinuation may have stronger claims. Additionally, the labeling includes warnings about serious hypersensitivity reactions, such as anaphylaxis and angioedema, which have been reported with Ozempic and other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, no specific warning for gastroparesis is included in the warnings and cautions section, which raises questions about the adequacy of warnings regarding this potential harm.

Summary and Implications for Affected Patients

In summary, Ozempic use is associated with a significant increase in gastrointestinal adverse reactions, including symptoms that overlap with gastroparesis. The pharmacologic mechanism of delayed gastric emptying provides a plausible pathway for the development of gastroparesis. The absence of explicit warnings in the labeling may be a factor in litigation. Patients affected by gastroparesis potentially linked to Ozempic should consider the timing of symptom onset relative to drug exposure and the adequacy of informed consent regarding this risk. References: (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it diagnosed?

Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction. Symptoms include nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which a radiolabeled meal leaves the stomach.

What evidence links Ozempic to gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its therapeutic mechanism. Clinical trials show a higher incidence of gastrointestinal adverse reactions in Ozempic users compared to placebo, including nausea, vomiting, and diarrhea. The pharmacodynamic effect on gastric motility provides a plausible mechanistic link to gastroparesis, although the labeling does not explicitly list gastroparesis as an adverse reaction.

What are the settlement criteria for an Ozempic gastroparesis lawsuit?

Settlement criteria typically require documented Ozempic exposure and a confirmed diagnosis of gastroparesis. Additional factors include the timing of symptom onset relative to drug use, severity and duration of symptoms, and evidence that the condition is not due to other causes. The adequacy of warnings regarding gastroparesis risk may also be considered.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Labeling for Ozempic

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.